Back to Search
Start Over
Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
- Source :
- Annals of the Rheumatic Diseases
- Publication Year :
- 2019
- Publisher :
- BMJ, 2019.
-
Abstract
- Methotrexate (MTX) is known to improve blood levels and clinical outcome to anti-tumour necrosis factor (anti-TNF) therapy by reducing the formation of antidrug antibodies.1 Recent findings indicate that MTX prevents immunisation against TNF inhibitors through de novo purine biosynthesis inhibition and generation of immunosuppressive adenosine.2 This effect is mediated by activation of MTX prodrug to MTX polyglutamates (MTXPG), and we previously reported that MTXPG levels were associated with improved steady state levels of infliximab.3 In this study, we extended these observations and evaluated the impact of MTXPG on adalimumab and etanercept levels. The study was cross-sectional by design, multicentred (three sites) and enrolled 169 consecutive consented adult rheumatoid arthritis subjects under MTX in combination with adalimumab (83 subjects) or etanercept (86 subjects). All patients enrolled were inadequate responders to MTX prior to starting anti-TNF therapy and had received MTX with anti-TNF therapy for least 3 months. At the time of a single visit, anticoagulated blood was collected randomly …
- Subjects :
- Male
musculoskeletal diseases
0301 basic medicine
medicine.medical_specialty
Letter
Necrosis
Immunology
anti-tnf
Gastroenterology
methotrexate
General Biochemistry, Genetics and Molecular Biology
Etanercept
Arthritis, Rheumatoid
03 medical and health sciences
0302 clinical medicine
Rheumatology
Pharmacokinetics
immune system diseases
Internal medicine
medicine
Adalimumab
Humans
Immunology and Allergy
skin and connective tissue diseases
030203 arthritis & rheumatology
business.industry
Middle Aged
Prodrug
medicine.disease
Treatment Outcome
030104 developmental biology
Polyglutamic Acid
Antirheumatic Agents
Rheumatoid arthritis
Drug Therapy, Combination
Female
Methotrexate
Tumor necrosis factor alpha
medicine.symptom
business
pharmacokinetics
medicine.drug
Subjects
Details
- ISSN :
- 14682060 and 00034967
- Volume :
- 78
- Database :
- OpenAIRE
- Journal :
- Annals of the Rheumatic Diseases
- Accession number :
- edsair.doi.dedup.....8364801f33cc5b3026ff14d884ab0177
- Full Text :
- https://doi.org/10.1136/annrheumdis-2018-214860